Latest / Houston's Morning News on KTRH / Dr. Amy Ho Joins Houston's Morning News
Transcript
- 0:00Speaker 1: Okay, now it's five fifty two, and now my clock
- 0:02Speaker 1: actually works. Doctor Amy Hoach joining us to talk about
- 0:04Speaker 1: GLP one drugs and why and how it has just
- 0:07Speaker 1: taken over the healthcare industry.
- 0:08Speaker 2: Doctor, good morning, good morning, thanks for having me, Bob,
- 0:11Speaker 2: Thank you.
- 0:12Speaker 3: Sorry about the glitch there.
- 0:14Speaker 1: So doctor, talk about why it is that, you know,
- 0:17Speaker 1: I mean, health OBCD has been a problem, and you know,
- 0:21Speaker 1: overweight America has been long known for many decades. Obviously,
- 0:24Speaker 1: this is obviously a breakthrough, an astounding breakthrough here. Why
- 0:28Speaker 1: has this become the preferred method of treating obesity rather
- 0:32Speaker 1: than the age old tradition of diet and exercise.
- 0:35Speaker 2: I think the truth is diet and exercise availed, right Like,
- 0:38Speaker 2: we've been obese for a very long time. The American
- 0:41Speaker 2: Medical Association has called OBC a disease since twenty thirteen,
- 0:44Speaker 2: and yet we continue to be severely obese. And until
- 0:48Speaker 2: the golp ones came there was not really any effective
- 0:51Speaker 2: treatments except for bariatric surgery, which is fairly invasive. You
- 0:56Speaker 2: look at weight loss drugs and the most famous has
- 0:59Speaker 2: probably been which was pulled off because of its cardiac
- 1:03Speaker 2: risk factors, and so glp ones are probably the first
- 1:06Speaker 2: major safe of force of side effects but still safe
- 1:10Speaker 2: treatment for OBC. We've really ever had what.
- 1:13Speaker 1: Are the major drawbacks for this, because you know a
- 1:15Speaker 1: lot of people have said, you know, we as a nation,
- 1:19Speaker 1: a lot of people refuse to take the mRNA jabs
- 1:22Speaker 1: during COVID because there were no long term trials seeing
- 1:25Speaker 1: what the real long term.
- 1:25Speaker 3: Side effects are going to be. But everybody's willing.
- 1:28Speaker 1: Did you have these subcutaneous, you know, injections into them
- 1:31Speaker 1: to lose weight.
- 1:32Speaker 3: Without those long term trials as well? What are the risks?
- 1:36Speaker 2: Well, so glp ones have actually been around for quite
- 1:38Speaker 2: some time. They've been used primarily for diabetes. So the
- 1:41Speaker 2: obesity indication is new, but the drugs themselves are actually
- 1:45Speaker 2: not new.
- 1:46Speaker 3: When you look at.
- 1:47Speaker 2: The side effects of glp ones, there are things that
- 1:50Speaker 2: you expect, right like there's going to be lean muscle
- 1:54Speaker 2: mass loss. There might be some bone loss as well,
- 1:58Speaker 2: and all that as a result of its prime mechanism,
- 2:00Speaker 2: which is actually to decrease your weights, and so that's
- 2:05Speaker 2: really expected. You also see a lot of GI effects obviously, nausea,
- 2:10Speaker 2: delayed stomach emptying. Some this can actually persist after you're
- 2:15Speaker 2: off the medication. Which is probably the number one thing
- 2:17Speaker 2: that I see in the emergency apartment is people with
- 2:20Speaker 2: abdominal issues after stopping GLP ones. But then after that,
- 2:25Speaker 2: all of the risk factors are extraordinarily rare. There's a
- 2:29Speaker 2: boxed warning about thyroid C cell tumors, but it's actually
- 2:33Speaker 2: not confirmed in humans, only in rodents, and the numbers
- 2:36Speaker 2: were extraordinarily small. There's some evidence about hospital gallstone issues,
- 2:42Speaker 2: pancreat hiatus, et cetera, but again the numbers on those
- 2:45Speaker 2: are exceedingly small. So it's all the GI effects and
- 2:47Speaker 2: the muscle mass loss effects that you would expect.
- 2:50Speaker 1: So one more question about safety, doctor ho, if we could.
- 2:54Speaker 1: There are the brand names, the ozempics and the Munjaros
- 2:59Speaker 1: and the other things like that, but then there are
- 3:01Speaker 1: like kind of offshoots of that, and I don't know
- 3:03Speaker 1: exactly what difference is, but cost wise, you know, the
- 3:06Speaker 1: big names are still extraordinarily expensive, and then there are
- 3:09Speaker 1: some I don't know if they're diluted or what they are.
- 3:11Speaker 1: But is the safety because sum are FDA approved and
- 3:15Speaker 1: the other ones are not. The ones that are ninety
- 3:17Speaker 1: nine dollars a month instead of five hundred and ninety
- 3:19Speaker 1: nine dollars a month.
- 3:20Speaker 3: So what's the real safety story there.
- 3:22Speaker 2: Yeah, so you're touching on something really important here, which
- 3:25Speaker 2: is that the cost of GLP ones is exceedingly high
- 3:28Speaker 2: for most people. It's around one thousand even more a month.
- 3:32Speaker 2: Many insurance don't cover it. There's a lot of controversy
- 3:35Speaker 2: about Medicaid and Medicare on how they cover it in
- 3:38Speaker 2: the programs that they have. So what you're touching on
- 3:40Speaker 2: is that if you don't actually get with GOVY and
- 3:44Speaker 2: you get a compound of it done by a compound pharmacy,
- 3:49Speaker 2: it is the same ingredient, but the dose may be
- 3:52Speaker 2: different in how is mixes different, so you'll see variable effects.
- 3:56Speaker 2: I haven't seen a whole lot of differences in the
- 3:59Speaker 2: side effects terms of the type of side effects people get,
- 4:02Speaker 2: but the dose is actually very different. So probably one
- 4:04Speaker 2: of the major things you see is because the dose
- 4:07Speaker 2: of the active ingredient and the efficacy of the ingredient
- 4:10Speaker 2: may be different when it's compounded at independent pharmacy versus
- 4:13Speaker 2: when it's the brand name what that went through drug trials,
- 4:16Speaker 2: that maybe people are losing fat too fast, and that's
- 4:20Speaker 2: really when you start to get into those issues of
- 4:22Speaker 2: muscle and bone loss at too quick of a rate
- 4:25Speaker 2: that can cause some effects, potentially long term and certainly cosmetically.
- 4:29Speaker 2: We've all heard about those zembic face or a zombic
- 4:31Speaker 2: but of people that lost mass too quickly.
- 4:36Speaker 1: That's a great point, and it's really important to note
- 4:38Speaker 1: the difference between the compounds and the originals as well.
- 4:41Speaker 1: And again one is the FDA proof for now and
- 4:43Speaker 1: the other ones are not yet. Doctor Amy Hope, thank
- 4:45Speaker 1: you so much for the insights. We appreciate it.
- 4:47Speaker 2: Thank you so much, Bob